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S U M M A R Y
Objectives: This study sought to assess if there is a meaningful way in which variations in sexually
transmitted infection (STI) prevalence can be classiﬁed at the level of world regions.
Methods: Linear regression was performed to assess if the incidence and prevalence of six STIs (HIV,
herpes simplex virus type 2, chlamydia, gonorrhea, syphilis, and trichomoniasis) by world region was
positively correlated. Partitioning around medoids (PAM) was then used to assess if the regions of the
world can be classiﬁed according to the incidence and prevalence of these STIs.
Results: We found evidence that STI incidence/prevalence varies considerably in different regions
around the world. Linear regression revealed that the incidence and prevalence of certain STIs by world
region was positively correlated (Pearson’s correlation coefﬁcient varied from 0.664 to 0.985). PAM
provided support for dividing the world regions into two, three, or four STI incidence/prevalence
categories, but it provided most support for the two-category system. In each of these systems the East
Asia/Paciﬁc and North Africa/Middle East regions were in the lowest STI category and Sub-Saharan Africa
was the only region in the high STI category.
Conclusions: The incidence and prevalence of certain STIs by world region are positively correlated. The
world regions can be meaningfully classiﬁed according to STI incidence/prevalence.
 2013 The Authors. Published by Elsevier Ltd on behalf of International Society for Infectious
Diseases. 
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There are large differences in the prevalence and incidence of
particular sexually transmitted infections (STIs) between different
populations. These differences have been noted in sub-populations
within countries and in comparisons between countries and
between regions.1–3 This study aimed to assess if there is a
meaningful way in which these variations can be classiﬁed at the
level of world regions. A common classiﬁcatory strategy is to divide
the world into developed countries and developing countries –
with low and high STI prevalences, respectively.4–11 STI pre-
valences are, however, far from uniformly high in developing
countries and in some cases are lower than in developed countries.
A reasonable ﬁrst step in establishing a taxonomy of global STI
variation would be to map the distribution of the major STIs. This* Corresponding author.
E-mail address: chriskenyon0@gmail.com (C. Kenyon).
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http://dx.doi.org/10.1016/j.ijid.2013.09.014was the main aim of this study. We sought to map the distribution
of seven STIs (HIV, herpes simplex virus type 2 (HSV-2), human
papillomavirus (HPV), chlamydia, gonorrhea, syphilis, and tricho-
moniasis) and the sexually associated disease, bacterial vaginosis
(BV), by world region. Whilst previous publications have mapped
the global distribution of each of these STIs individually, none has
done this for all of these STIs simultaneously. Furthermore, no
study that we are aware of has assessed if the variations in
prevalence of these STIs support a classiﬁcation system of world
regions based on STI prevalence. A part of this mapping exercise is
an assessment of the extent to which six of these STI rates (HIV,
HSV-2, chlamydia, gonorrhea, syphilis, and trichomoniasis) co-
vary between regions. This is an important question, because if STI
rates do co-vary to a signiﬁcant extent, then this may be indicative
of a common risk factor driving the higher rates.
2. Methods
2.1. Incidence of syphilis, gonorrhea, chlamydia, and trichomoniasis
The World Health Organization (WHO) has published estimates
for the incidence and prevalence of four curable STIs by worldociety for Infectious Diseases. Open access under CC BY-NC-SA license.
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methodology used was broadly similar. Prevalences were estimat-
ed for the four STIs by sex and by world region. These estimates
were based on a literature review of STI prevalence in different
populations, WHO archival information from country-speciﬁc
reports, and other sources, such as ofﬁcial STI prevalence estimates
from developed countries. As far as the world-region classiﬁcatory
system utilized is concerned, the 1995 and 1999 publications
followed the United Nations (UN) standard regions, whereas the
2005 report used the WHO world regions. We used the estimates
from 1999, as we regard the nine world regions typology used in
this report to better reﬂect the heterogeneity of STI incidence and
prevalence than the six world regions typology of the 2005 report.
In addition the nine-region typology was more compatible with
the other data sources we utilized. (See Supplementary Material
Table 1 for a list of countries by UN standard regions.) An example
of the difference this makes is provided by the Americas. In the
1995 and 1999 reports, Latin America and the Caribbean are one
region and North America another. Their signiﬁcantly different
rates of STIs are lost in the 2005 report, where both these regions
are combined into one. Regional adult prevalence for each infection
was calculated using mid-year population estimates for 15–49-
year-olds. The duration of infection was then estimated by sex and
by region. These estimates were based on the probability a
symptomatic or asymptomatic person would get treatment for
their STI. To calculate regional STI incidence for adults, the
estimated prevalence was divided by the estimated duration of
each disease. The 1999 report only reported regional incidence and
prevalence ﬁgures for each STI in total numbers of cases. We
calculated the incidence and prevalence per million 15–49-year-
olds using mid-year population estimates of 15–49-year-olds. The
population estimates we used were 2003 (mid-year) ﬁgures
obtained from the United States Census Bureau.16
Supplementary data associated with this article can be found, in
the online version, at http://dx.doi.org/10.1016/j.ijid.2013.09.014.
2.2. HIV
Regional HIV prevalence data for 15–49-year-olds for 2003 and
2009 were obtained directly from the 2003 and 2010 UNAIDS
Global AIDS reports.17,18
2.3. HSV-2
Age- and gender-speciﬁc HSV-2 prevalences were obtained
from the review of Looker et al.;19 this is a systematic review of
studies investigating HSV-2 incidence and prevalence from 1966 to
2005. For each of the world’s 12 regions, pooled prevalence values
by age and gender were generated for the year 2003, in a random-
effect model. Prevalence was reported as the total number HSV-2-
seropositive. Only surveys from general populations were includ-
ed. Since this study reported only the total number of persons
estimated to be HSV-2-seropositive in each region, we calculated
the prevalence as the percentage of the population HSV-2-
seropositive in 2003. The population estimates we used were
2003 (mid-year) ﬁgures obtained from the United States Census
Bureau.16 The indicator we chose to represent HSV-2 prevalence
was female HSV-2 prevalence in 40–44-year-olds. HSV-2 preva-
lence increases monotonically with age in all populations around
the world until at least age 44 years.20 HSV-2 prevalence in men
and women co-vary fairly closely by country and region, but HSV-2
prevalence in women is generally higher than in men. We chose
the percentage of 40–44-year-old women who were seropositive
for HSV-2 as our indicator of HSV-2 prevalence, as a narrow age
band was least likely to be affected by differences in age
composition between regions, and older female prevalence wasmost likely to demonstrate differences in HSV-2 prevalence by
region. To make the Looker et al. regions coterminous with the UN
standard regions, we combined their data for Japan and the Paciﬁc
with those of East Asia, and the data from South Asia with those
from Southeast Asia (see Supplementary Material Table 1).
2.4. HPV
HPV prevalences were taken from a meta-analysis and a
systematic literature review of global HPV prevalence. Studies
published between January 1995 and January 2005 were used.21
Inclusion criteria included the following: studies required detailed
descriptions of study populations, methods used to collect cervical
samples, and assays used for HPV DNA detection and typing. Only
women with normal cervical cytology were included in the survey.
Final analyses included 78 studies that could be separated into
women with normal cytology, and 44 of these had data on age-
speciﬁc HPV prevalence. For our study we excluded regional data
that depended on a single study of less than 500 women. This
excluded Eastern Europe, which had only a single study of 309
women, and North Africa and the Middle East, which had a single
study of 172 women. The other regions were represented by studies
that included between 6226 and 69 820 women. HPV regional
prevalence estimates were adjusted for a broad range of factors,
including geographical region, study sample type, study design, and
age. To make the regions from the HPV prevalence data coterminous
with the UN standard regions, we combined their data for Japan and
Taiwan with those of East Asia, the data from South Asia with those
from Southeast Asia, and the data from Central America with those of
South America (see Supplementary Material Table 1).
2.5. Bacterial vaginosis
BV prevalences were obtained from a recent systematic review
of the global patterning of BV.22 This review included only 46
studies that were representative population-based or antenatal-
based samples, and the diagnosis of BV was based on Nugent’s
scoring system, a scoring system based on Gram stains of vaginal
secretions. For the purposes of comparing BV by region, a BV
summary indicator was developed, which is deﬁned as the
percentage of studies done in a particular world region that
revealed a BV prevalence of 30%.
2.6. STI mortality data
The combined mortality from gonorrhea, syphilis, and chlamydia
by country in 2002 are estimates taken from the World Health
Report, 2004.23 The WHO derived these data from 112 national vital
registration systems that capture about one third of deaths
occurring in the world. Population laboratories and epidemiological
analyses of speciﬁc conditions were then used to improve the
estimates. The deaths are coded according to International
Statistical Classiﬁcation of Diseases and Related Health Problems
(ICD) classiﬁcation rules. We reclassiﬁed the countries according to
the UN standard regions and then recalculated the total numbers of
persons who live in these regions and the numbers who died from
the three STIs per region. We used these two ﬁgures to calculate the
estimates for the death rate associated with these STIs per million
population per region in 2002.
2.7. Statistical analysis
We used partitioning around medoids (PAM) clustering based
on Euclidean distance, to classify world regions according to STI
incidence/prevalence. PAM clustering is a statistical technique of
grouping entities from a dataset that have a high degree of
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minimum distance between points labeled to be in a cluster and a
point designated as the center of that cluster.24 So as to reduce the
dimensionality of the dataset and improve the likelihood of
discovering stable clusters, we limited the STI variables we used to
the six with the best geographical coverage and quality. These
were the incidence of chlamydia, gonorrhea, syphilis, and
trichomoniasis and the prevalence of HSV-2 and HIV. HPV was
omitted as there were no data for three regions and for ﬁve regions
no overall prevalence was calculated. Estimated deaths from
curable STIs was not used due to the fact that it is not a direct
measure of the incidence or prevalence of STIs. BV was omitted due
to the incompleteness of the data22 and the debate as to whether it
is a sexually associated or a sexually transmitted disease.25 As far
as the cluster number (k) is concerned, we repeated the analysis
three times with k = 2, 3, or 4. The cohesiveness of the various
clustering solutions was analyzed using average silhouette
width.26 The silhouette width measures a combination of intra-
cluster homogeneity and inter-cluster separation. It thus measures
how close an observation is to its own cluster compared to the
other clusters. Higher values indicate better clustering.
We used multivariate analysis of variance (MANOVA) to test if
the mean prevalence/incidence of the six selected STIs were
different between the clusters. This was done separately for
classiﬁcations based on two, three, and four clusters.
Linear regression (with Bonferroni corrections for multiple
comparisons) was used to evaluate how correlated the incidence/
prevalence of the six STIs by region were with one another. All
statistical analyses were performed in R (version 2.15.1).
Ethical consideration was not necessary since secondary data
were used and all previous work by other authors was duly cited.
3. Results
Evidence was found of considerable heterogeneity in the
incidence and prevalence of the seven STIs investigated around
the world (see Tables 1 and 2, and Figure 1). The incidence and
prevalence of certain of these STIs were correlated. This effect was
the strongest for gonorrhea incidence, which was signiﬁcantly
correlated with each of the other ﬁve STIs (see Table 2). The effect
was weakest for syphilis incidence, which was only signiﬁcantly
correlated with the incidence of gonorrhea. All pairwise correla-
tions were positive, with their values ranging from 0.664 (HSV-2
vs. chlamydia, p = 0.767) to 0.985 (trichomoniasis vs. chlamydia,
p < 0.0001).
PAM analysis revealed evidence of clustering, which was
strongest for a typology that divided the world into two areas –
high (Sub-Saharan Africa) and low (other regions) STI prevalence
(average silhouette width 0.58; see Figure 2 and Table 3). There
was also support (though progressively less) for a three- and four-
area typology. In the three-area classiﬁcation, East Asia/Paciﬁc
and North Africa/Middle East would be low prevalence, Sub-
Saharan Africa high prevalence, and the remaining regions
intermediate prevalence (average silhouette width 0.45). The
four-area system would be the same as the three-area system
except that South/Southeast Asia and Latin America/Caribbean
would become a new high-intermediate prevalence band (aver-
age silhouette width 0.39).
MANOVA revealed support for a classiﬁcation based on two
clusters (p = 0.037) and three clusters (p = 0.001).
The extent to which STIs were correlated by region was further
illustrated by considering how infrequently the ranges of STI
incidence/prevalence for each of the six STIs considered over-
lapped between adjoining clusters (see Tables 1 and 3). When the
regions were divided into two clusters, there was no overlap
between the ranges of incidence/prevalence for any of the six STIsbetween the high and low prevalence clusters. When using the
three-cluster system, there were only three overlaps in ranges (for
HSV-2, HIV, and syphilis) and all of these were between the low
and intermediate prevalence clusters. The typology with the
weakest statistical support and the greatest number of categories
was the four-cluster system. Even with this system it was evident
that with few exceptions, the incidence/prevalence of the STIs
increased monotonically from the lowest to highest incidence area
– see Table 1. In the case of chlamydia, gonorrhea, syphilis, and
trichomoniasis there is no overlap between the ranges of incidence
of each STI between adjoining categories. The only two exceptions
are an overlapping range in the cases of syphilis and gonorrhea
between the low and low-intermediate rate areas. In the case of
HSV-2 and HIV, the relationship is weaker, with more frequently
overlapping ranges. The BV summary indicator was only elevated
in three regions – 5% and 30% in the two regions in the high-
intermediate category and 50% in the one region in the high
prevalence category. The HPV prevalences overlap frequently
between the different clusters. The regions with the highest and
second highest HPV prevalences are, however, in the high and
intermediate-high prevalence clusters, respectively.
The mortality data for the three curable STIs were broadly
commensurate with the classiﬁcatory system – being highest and
second highest in the high and intermediate-high categories,
respectively. The major anomaly with this variable was the
considerably higher mortality rate in the North Africa and Middle
East region (10.4) than all the other low STI prevalence regions
(0.6–0.9). This anomaly is, however, largely determined by Egypt
and Algeria. If one removes these two countries, the region’s
mortality rate drops to 2.4.
4. Discussion
A ﬁrst step in working out the determinants of a disease is
mapping the distribution of the disease.27 A commonly used
taxonomy of STI epidemiology divides the world into developed
and developing, with high and low STI prevalences, respectively.4–
11 The results of this study suggest that this approach is
insufﬁciently nuanced. In all three typologies suggested by
partitioning around medoids, the North African and Middle
Eastern region, through classiﬁed as developing,28 is in the lowest
STI prevalence category. The only other region that is in the lowest
STI prevalence category is East Asia, which includes a large number
of countries classiﬁed as developing – including China.28 Further-
more, there are signiﬁcant differences in STI prevalence between
the developing world regions. The traditional taxonomy obscures
the signiﬁcantly higher STI prevalences in Sub-Saharan Africa than
other developing world regions.
The traditional developed–developing world taxonomy
implies that certain dimensions of economic development act
as important determinants of STI prevalence. One widely cited
factor is that STI treatment improves with economic develop-
ment.4 There is not, however, to the best of our knowledge, any
evidence that STI treatment capacity is worse in high STI regions
such as Sub-Saharan Africa than in low prevalence regions such as
North Africa.29 If one regards access to antiretroviral therapy once
one meets the WHO 2009 criteria for therapy as a proxy for
national STI treatment capacity, then there is no correlation
between regional STI prevalence and treatment capacity (C.
Kenyon, unpublished data).
Furthermore, the relationship between poverty and STI
prevalence is far from a straightforward positive association as
implied by the traditional STI taxonomy. Certainly there is
evidence that social disruptions can result in increases in STI
incidence.30 Similarly in certain circumstances an association has
been demonstrated between markers of deprivation and STI
Table 1
Incidence, prevalence, and mortality of eight major STIs reported by world region, 1990–2006, arranged in a four-cluster typology (15–49-year-olds unless otherwise stated)a
Annual
incidence
of CT + NG
+ TP + TV
(per/1000)b
Annual incidence
of chlamydia
(per/1000)
Annual
incidence
of gonorrhea
(per/1000)
Annual
incidence
of syphilis
(per/1000)
Annual incidence of
trichomoniasis
(per/1000)
Adjusted HPV
prevalencec
HSV-2 prevalence
40–44-year-old
women (%)
HIV
prevalence
2003 (%)
HIV prevalence
2009 (% 15–
49-year-olds)
BV summary
indicator,%
studies
NSS 30% (n)d
Estimated
deaths from
syphilis,
gonorrhea,
and chlamydia
(per million
inhabitants)
Low
East Asia and Paciﬁc 22.1 6.5 4.0 0.3 11.7 7–13.6e 26.7 0.1–0.1 0.1 0 (2) 0.9
North Africa and Middle East 60.6 19.1 8.9 2.2 27.9 15.4 0.2–0.4 0.2 0 (6) 10.4
Range 22.1–60.6 6.5–19.1 4–8.9 0.3–2.2 11.7–27.7 7–13.6 15.4–26.7 0.1–0.2 0–0 0.9–10.4
Intermediate-low
Australia and New Zealand 90.9 27.3 10.9 0.7 55.4 22.3 0.1–0.1 0.1 0 (2) 0.6
Western Europe 83.7 25.7 5.5 0.7 52.3 7.6 17.2 0.3–0.3 0.2 0 (10) 0.6
North America 89.7 25.2 10 0.7 52.4 11.3 29.5 0.5–0.7 0.5 0 (6) 0.6
Eastern Europe and Central Asia 107.3 29.1 16.2 0.5 63.9 25.9 0.5–0.9 0.8 0 (1) 1.2
Range 83.7–107.3 25.2–29.1 5.5–16.2 0.5–0.7 52.4–63.9 7.6–11.3 17.2–29.5 0.1–0.8 0–0 0.6–2
Intermediate-high
South and Southeast Asia 151.8 43.1 27.3 4.1 76.8 6.2–7.5e 16.1 0.4–0.8 0.3 5 (19) 41.2
Latin America and Caribbean 146.2 35.8 27.9 11.2 70.4 12.3–20.4e 38.8 0.5–3.1f 0.5 30 (10) 3.0
Range 146.2–151.8 43.1–35.8 27.3–27.9 4.1–11.2 70.4–76.8 6.2–20.4 16.1–38.8 0.3–0.5 5–30 3–41.2
High
Sub-Saharan Africa 256.5 59.1 63.3 14.2 119.4 22.1 69.3 7.5–8.5 5.0 50 (12) 139.2
Total 111.8 30.3 20.5 3.9 57.0 40.8 0.8
BV, bacterial vaginosis; HIV, human immunodeﬁciency virus; HPV, human papillomavirus; HSV-2, herpes simplex virus type 2; NSS, Nugent score system; STI, sexually transmitted infection.
a All prevalences excluding those for BV, HPV, and HSV-2 are for 15–49-year-olds.
b Annual incidence of chlamydia (CT), gonorrhea (NG), syphilis (TP), and trichomoniasis (TV) combined.
c Prevalence estimates are adjusted for region, study type, study design, publication year, sampling collection device, cell storage medium, HPV assay, primer used, youngest age included, and oldest age included in each study.
d BV summary indicator refers to the percentage of studies done in thewhole region that revealed a BV prevalence of30%. Only studies using the NSSwere used in these calculations (number of studies with BV prevalence30%/
total number of studies using NSS  100).
e In the case of HPV, prevalences were reported separately for Eastern Asia (13.6%) and Japan/Taiwan (7%), as well as for South Asia (6.6%) and Southeast Asia (6.2%) and South America (12.3%) and Central America (20.5%).
f Separate HIV prevalences were reported for Latin America (0.5–0.7%) and the Caribbean (1.9–3.1%).
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Figure 1. The annual incidence of chlamydia (A), gonorrhea (B), syphilis (C), and trichomoniasis (D) per 1000, by world region. The prevalence of HPV (E), HSV-2 (F), and HIV
(G) by world region. All the ﬁgures are for 15–49-year-olds, except HPV and HSV-2. (Various sources of data detailed in the Methods section.).
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Table 2
Correlation matrix shows Pearson’s pairwise correlations (rho) and p-values corrected for multiple comparisons (p-values given in parenthesis)
Chlamydia Gonorrhea Syphilis Trichomoniasis HSV-2 HIV
Chlamydia 1 0.919
(0.007)
0.787
(0.178)
0.985
(0.00002)
0.664
(0.767)
0.763
(0.251)
Gonorrhea 1 0.903
(0.013)
0.907
(0.011)
0.859
(0.045)
0.906
(0.011)
Syphilis 1 0.763
(0.252)
0.830
(0.084)
0.758
(0.270)
Trichomoniasis 1 0.714
(0.460)
0.788
(0.175)
HSV-2 1 0.917
(0.008)
HIV 1
HIV, human immunodeﬁciency virus; HSV-2, herpes simplex virus type 2.
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country-level HIV prevalence is not associated with the percentage
of the population living in poverty or the GDP per capita.32 In fact
HIV prevalence has been shown to be positively associated with
increasing wealth at an individual level in Sub-Saharan Africa.33,34
An important ﬁnding of this study, and one that is worthy of
further exploration, is the correlation between the incidence/
prevalence of certain STIs by region. The fact that the STIs
evaluated here include such a broad range of viral, prokaryotic, and
eukaryotic organisms makes it less likely that differential genetic
susceptibility is responsible for these different STI rates. It is also
signiﬁcant that both the curable and incurable STIs (HSV-2, HIV)
co-vary according to these STI prevalence regions – suggesting that
differential STI treatment efﬁcacy is not a dominant factor in
explaining variations in STI rates.
There are a number of limitations of our study. Chief amongst
these is the quality of the data. There is a severe paucity of
population-based STI incidence and prevalence data from much of
the world. The data used here were all based on various statistical
techniques to estimate regional STI rates. Issues relating to data
quality and the various methods used to estimate STI rates
precluded the use of statistical tests to compare results. Each of
these techniques used to estimate STI rates can be faulted. There
were, however, relatively few changes in the results in the four
reviews of curable STIs the WHO has performed, despite the fact
that three different methodologies were used. The seroprevalence
of HIV is based on fairly high quality survey data representing a
large proportion of the world’s countries.18 The fact that data from
such different sources, such as death registries and serological
surveys, provided information that was concordant and also inFigure 2. Results of partitioning according to medoids clustering in two (A), three (B), or 
two-dimensional space of the ﬁrst two principal components – the axes labeled com
prevalence/incidence variables that accounts for the largest possible proportion of v
variability).agreement with the high quality HIV prevalence data, provides
some reassurance as to the quality of the data. Further support
comes from the fact that studies that have compared the global
contouring of other STIs, such as donovanosis and chancroid, have
found the prevalence in Sub-Saharan African to be as high or higher
than in all other world regions.35,36
A signiﬁcant difference between the WHO 2005 report and
earlier reports is that chlamydia prevalence and incidence are no
longer highest in Sub-Saharan Africa. This may be due to a number of
factors including: changes in the methodology used in the 2005
report to estimate prevalence/incidence and behavior change in
response to HIV reducing chlamydia incidence in Sub-Saharan
Africa. A further possibility is that the AIDS-related deaths have
altered the connectivity of local sexual networks in a way that has
reduced the efﬁcacy of STI transmission.37 Evidence of this effect has
been demonstrated in the initial post AIDS decline in syphilis among
men who have sex with men in the USA.38 Indirect evidence of this
effect has been adduced in the case of chlamydia and gonorrhea in
Sub-Saharan Africa.39 These ﬁndings point to the complexity of the
interactions between the different determinants of STI transmission
and the resultant effect of differential transmission of the various
STIs.37 This point was reinforced by an elegant sexual network study
from Canada, which showed that differences in the structure of
sexual networks between Aboriginal and non-Aboriginal popula-
tions explained a signiﬁcant part of the differences of STI prevalence
between these populations. A notable ﬁnding of the study was that
different networks had different effects on the spread of various STIs.
As an example, the network clusters most prevalent in non-
Aboriginal populations were found to be conducive to the
transmission of chlamydia but not gonorrhoea.40four (C) pre-speciﬁed clusters. In each plot, the world regions are plotted within the
ponents 1 and 2. Each component represents a linear combination of the six STI
ariance of the original data (these two components explain 94.39% of the point
Table 3
The results of partitioning around medoids to classify the world’s regions according to STI incidence/prevalence
Two clusters Three clusters Four clusters
East Asia and Paciﬁc Low Low Low
North Africa and Middle East Low Low Low
Australia and New Zealand Low Intermediate Intermediate low
Western Europe Low Intermediate Intermediate low
North America Low Intermediate Intermediate low
Eastern Europe and Central Asia Low Intermediate Intermediate low
South and Southeast Asia Low Intermediate Intermediate high
Latin America and Caribbean Low Intermediate Intermediate high
Sub-Saharan Africa High High High
Average silhouette width 0.58 0.45 0.39
STI, sexually transmitted infection.
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by a wide range of factors, such as treatment efﬁcacy,37
population levels of immunity,41 interactions with other STIs,42
socio-economic and other upstream factors,37 circumcision
prevalence,43 and sexual behavior (individual and network-
levels).37 As illustrated by the Canadian study described above,
these constitutive causal factors may combine to have different
effects on STI incidence for different STIs. The complexity, speed,
and magnitude of the changes in STI incidence pose a large
problem to any endeavor to classify world regions based on STI
prevalence.30 This is particularly the case when the data used are
cross-sectional and ecological. The ecological nature of the study
will in addition likely obscure differences in the extent to which
aggregate regional ﬁgures for STIs in different regions are
inﬂuenced by concentrated epidemics in sub-groups/countries.
The difﬁculties with measuring STI incidence and prevalences
accurately would, however, introduce a misclassiﬁcation bias
that should act to attenuate the differences in STI rates between
regions.
This study suggests that the patterning of STIs in the time
period investigated does co-vary to a considerable extent and
that this covariance does not follow the developed–developing
world dichotomy. In particular the high rates of STIs in Sub-
Saharan Africa need further investigation. The increased sexual
network connectivity in the region has been linked by some to
the higher HIV prevalence in the region.1,44 Although there is a
considerable body of evidence concerning the importance of
network connectivity-related risk factors such as partner
concurrency in the spread of other STIs,45,46 there is consider-
able debate about the importance of concurrency47,48 and little
has been published on this from Sub-Saharan Africa.49,50
There is a considerable need for more research to more
accurately map the global variations in STI rates, as well as the
risk factors underpinning STI spread. This work would beneﬁt
from more accurate population-based STI incidence and preva-
lence data. It would also be enriched by situating it within a
multilevel framework for understanding the spread of STIs.49,50
Such a framework should include regional, national, and sub-
national population data, important contextual data (such as
gender, socioeconomic variables, and ethnicity), and sexual
behavior data that includes individual-, partner- and network-
level data. The establishment of a multilateral agency or
research group whose task it is to perform these more detailed
mapping studies for STIs would be one way to facilitate this
process.
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